GT BIOPHARMA, INC. Other Nonoperating Gains (Losses)
GT BIOPHARMA, INC. (GTBP) reported Other Nonoperating Gains (Losses) of $12.60 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-04-16.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingGainsLosses · last filed 2021-04-16
- GT BIOPHARMA, INC. other nonoperating gains (losses) for fiscal 2020 was $12.60M.
- GT BIOPHARMA, INC. other nonoperating gains (losses) for fiscal 2019 was $0.00.
| Period end | Other Nonoperating Gains (Losses) 12 month |
|---|---|
| 2020-12-31 | $12.60M 10-K · filed 2021-04-16 |
| 2019-12-31 | $0.00 10-K · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |